| Source: |
Escherichia coli |
| Molecular Weight: |
Approximately 8.0 kDa, a single, non-glycosylated polypeptide chain containing 70 amino acids. |
| AA Sequence: |
LGASWHRPDK CCLGYQKRPL PQVLLSSWYP TSQLCSKPGV IFLTKRGRQV CADKSKDWVK KLMQQLPVTA |
| Purity: |
> 97% by SDS-PAGE and HPLC analyses. |
| Biological Activity: |
Fully biologically active when compared to standard. The specific activity is determined by the inhibitory effect on monocyte migration response to human MIP-1 alpha using a concentration range of 1.0µg-10.0µg/mL of viral MIP-2 will inhibit 25ng/mL of human MIP-1 alpha. |
| Physical Appearance: |
Sterile filtered white lyophilized (freeze-dried) powder. |
| Formulation: |
Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM PB, pH7.4, 150 mM NaCl. |
| Endotoxin: |
Less than 1 EU/μg of rViMIP-2 as determined by LAL method. |
| Reconstitution: |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions. |
| Stability & Storage: |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month, 2 to 8°C under sterile conditions after reconstitution.
3 months, -20 to -70°C under sterile conditions after reconstitution. |
| Synonyms: |
Viral Macrophage Inflammatory Protein II, vMIP-1B, MIP-II, vMIP-2 |
| Background: |
Viral MIP-2 is one of three chemokine-like proteins expressed by human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus, KSHV), along with ViMIP-1 and ViMIP-3. It shares 41% sequence similarity with human MIP-1α and 48% with ViMIP-1. ViMIP-2 exhibits antagonist activity towards a broad spectrum of chemokine receptors, effectively blocking infection by various strains of human immunodeficiency virus type 1 (HIV-1). This protein likely plays a role in evading host defenses, contributing to virus-induced neoplasia, and may be significant in the interactions between KSHV and HIV-1. Additionally, ViMIP-2 has been shown to activate and attract human eosinophils. |
